Sequoia Capital · Video summary

Biology's Waymo Moment: Ginkgo Bioworks' Jason Kelly

Biology is entering its "Waymo Moment" with AI, transforming it from an experimental science into an engineering discipline capable of autonomous labs and rapid discovery.

Sequoia Capital · March 24, 2026 · 58-min episode · 6-min read

Biology's Waymo Moment: Ginkgo Bioworks' Jason Kelly

Key takeaways

💡Biotechnology has historically been isolated from tech revolutions like the internet; AI is poised to fundamentally disrupt bio-pharma by making biology programmable.00:04
🚀Explore how AI and autonomous lab technologies are reshaping R&D in your industry or investment portfolio.00:04
🎯The core challenge in programming cells is the inefficiency of the compile-debug cycle for DNA code, which involves physical processes of building, testing, and iterating on biological designs.03:38
🚀AI can revolutionize scientific discovery by enabling autonomous labs to perform experimental science, moving beyond simulation to physical testing and rapid iteration.09:27
📈The partnership with OpenAI demonstrated that a reasoning model, given a robotic lab, can outperform human-led optimization in experimental science, achieving a 40% improvement in self-free protein synthesis.10:55
🔧Future scientific progress will be driven by AI reasoning models designing experiments and autonomous labs executing them, creating a feedback loop that dramatically accelerates discovery.12:36

Chapters

0:00🚀 Introduction: Tech's Impact on Biotech
0:46🏢 Ginkgo Bioworks' Founding and Early Challenges
1:38💡 The Y Combinator Connection
2:15🧬 Making Biology Programmable
3:24🔬 The Two Pillars of Engineering Biology
4:33💻 Design vs. Testing in Biology
5:04⚙️ Focus on the Backend: Accelerating Experiments
6:30🤔 The Nature of Scientific Problems
7:14🌎 Biology as a Substrate
8:24🤖 The OpenAI Partnership and Autonomous Labs
9:42🧪 Self-Free Protein Synthesis Experiment
11:24🧠 The Logic of Experimental Science
12:33🔄 The Future of the Scientific Method
14:21📈 Information Sharing and Efficiency in AI Labs
15:46💰 Cost Efficiency of Autonomous Labs
20:27🌐 The 'Waymo Moment' for Labs
23:22🧩 Challenges in Lab Automation: Integration and Liquid Handling
26:32👩‍🔬 The Scientist's Role and UI for Automation
28:22🚫 No Future for Humanoids in Labs
29:39🏠 Lab Space Reduction and Cloud Labs
31:30📦 Ginkgo's Business Model: Autonomous Labs and Cloud Services
32:43🔄 Training AI Models with Lab Data
35:24🇺🇸 Project Genesis and US Competitiveness
38:13🇨🇳 The Rise of China in Scientific Discovery
40:09🔬 Fundamental Research vs. Engineering
42:48💡 Breakthroughs Driven by AI
43:27🍎 AI in Chip Design: AlphaChip Example
44:57💸 Venture Capital and the Cost of Creation
45:44🧬 DNA-Native Models vs. Language Models
47:45💊 Therapeutics as the Primary Biotech Application
50:16📈 The Problem of Manual Work in Drug Development
51:33💡 The Future of Consumer Biotech Applications
54:52🩸 Molecular Monitoring for Health Interventions
56:30🔬 Democratizing Science Through Lower Costs
57:46🔮 Vision for the Future of Scientific Discovery

The digest

Biology's AI Moment: How Ginkgo Bioworks is Programmably Reshaping Scientific Discovery

This discussion with Jason Kelly, founder and CEO of Ginkgo Bioworks, explores the profound impact of AI on biotechnology and biopharma. It argues that unlike previous tech revolutions which had minimal impact on these fields, AI is poised to fundamentally disrupt how science is conducted and how industries like biopharma operate. The conversation delves into Ginkgo's journey, its core mission of making biology programmable, and the evolution of its "foundry" model. It highlights the critical role of AI in accelerating experimental science, the challenges and opportunities in creating autonomous labs, and the potential for a dramatic increase in the pace and accessibility of scientific discovery.